Trial Profile
A Multicenter Longitudinal Observational Study to Assess the Effectiveness of Fimasartan-based Antihypertensive Treatment and Prognosis in Post-Acute Phase of Ischemic Stroke or Transient Ischemic Attack
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2019
Price :
$35
*
At a glance
- Drugs Fimasartan (Primary)
- Indications Secondary hypertension
- Focus Therapeutic Use
- Acronyms FABULOUS
- Sponsors Boryung Pharmaceutical
- 01 Nov 2019 Status changed from recruiting to completed.
- 01 Aug 2017 New trial record